×
About 2,665 results

ALLMedicine™ Von Willebrand Disease Center

Research & Reviews  909 results

Harmonizing platelet function analyzer testing and reporting in a large laboratory netw...
https://doi.org/10.1111/ijlh.13907
International Journal of Laboratory Hematology; Favaloro EJ, Mohammed S et. al.

Jun 28th, 2022 - The platelet function analyzer (PFA) is a popular platelet function screening instrument, highly sensitive to von Willebrand disease (VWD) and to aspirin therapy, with moderate sensitivity to defects in platelet function and/or deficiencies in pla...

Post-procedural bleeding rate and haemostatic treatment use for dental procedures befor...
https://doi.org/10.1111/hae.14609
Haemophilia : the Official Journal of the World Federatio... Champagne PA, Bourassa M et. al.

Jun 26th, 2022 - Persons with inherited bleeding disorders are at a substantial risk of bleeding following dental procedures. To compare the outcomes and use of haemostatic treatment pre- and post-implementation of a standardized protocol for dental procedures at ...

Recent advances in therapeutic options for rare hemostatic disorders: selected poster e...
https://doi.org/10.1080/17474086.2022.2074395
Expert Review of Hematology; Jain N, Oldenburg J et. al.

Jun 25th, 2022 - Hemophilia, von Willebrand disease (VWD), and thrombotic thrombocytopenic purpura (TTP) are rare diseases affecting normal hemostasis. Although they differ in their pathogenesis and clinical manifestation, if left undiagnosed and untreated, all th...

Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into util...
https://doi.org/10.1016/j.leukres.2022.106903
Leukemia Research; Rippel N, Tremblay D et. al.

Jun 20th, 2022 - Anagrelide (ANA) is a platelet-specific cytoreductive agent utilized in the guideline-directed management of high-risk essential thrombocythemia. In the context of polycythemia vera (PV), ANA is occasionally employed in clinical practice, although...

Performance Evaluation of Von Willebrand:Collagen-Binding Assays to Diagnose Von Willebrand Factor Deficiency in Patients With Increased Risk of Bleeding
https://clinicaltrials.gov/ct2/show/NCT02792205

Jun 10th, 2022 - Von Willebrand Disease (VWD) is defined as an inherited bleeding disorder that is caused by deficiency or dysfunction of von Willebrand factor (VWF), a plasma protein that mediates the initial adhesion of platelets at sites of vascular injury and ...

see more →

Guidelines  4 results

No. 163-Gynaecological and Obstetric Management of Women With Inherited Bleeding Disord...
https://doi.org/10.1016/j.jogc.2017.11.036
Journal of Obstetrics and Gynaecology Canada : JOGC = Jou... Demers C, Derzko C et. al.

Feb 16th, 2018 - The prevalence of bleeding disorders, notably von Willebrand disease (vWD), among adult women with objectively documented menorrhagia is consistently reported to be 10% to 20% and is even higher in adolescents presenting with menorrhagia. Diagnost...

Evidence-based recommendations on the treatment of von Willebrand disease in Italy.
https://doi.org/10.2450/2008.0052-08
Blood Transfusion = Trasfusione Del Sangue; Mannucci PM, Franchini M et. al.

Jun 9th, 2009 - von Willebrand disease (VWD) is the most common hereditary bleeding disorder affecting both males and females. It arises from quantitative or qualitative defects of von Willebrand factor (VWF) and causes bleeding of mucous membranes and soft tissu...

Clinical and laboratory diagnosis of von Willebrand disease: a synopsis of the 2008 NHL...
https://doi.org/10.1002/ajh.21405
American Journal of Hematology; Nichols WL, Rick ME et. al.

May 6th, 2009 - Von Willebrand factor (VWF) mediates blood platelet adhesion and accumulation at sites of blood vessel injury, and also carries coagulation factor VIII (FVIII) that is important for generating procoagulant activity. Von Willebrand disease (VWD), t...

von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the N...
https://doi.org/10.1111/j.1365-2516.2007.01643.x
Haemophilia : the Official Journal of the World Federatio... Nichols WL, Hultin MB et. al.

Mar 5th, 2008 - von Willebrand disease (VWD) is a commonly encountered inherited bleeding disorder affecting both males and females, causing mucous membrane and skin bleeding symptoms, and bleeding with surgical or other haemostatic challenges. VWD may be disprop...

see more →

Drugs  19 results see all →

Clinicaltrials.gov  65 results

Performance Evaluation of Von Willebrand:Collagen-Binding Assays to Diagnose Von Willebrand Factor Deficiency in Patients With Increased Risk of Bleeding
https://clinicaltrials.gov/ct2/show/NCT02792205

Jun 10th, 2022 - Von Willebrand Disease (VWD) is defined as an inherited bleeding disorder that is caused by deficiency or dysfunction of von Willebrand factor (VWF), a plasma protein that mediates the initial adhesion of platelets at sites of vascular injury and ...

ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
https://clinicaltrials.gov/ct2/show/NCT04398628

May 25th, 2022 - This is a longitudinal, natural history observational cohort study being conducted at approximately 150 ATHN-affiliated sites. Participants will be followed for a minimum of 15 years. Harmonized data elements will be collected at time of enrollmen...

To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD)
https://clinicaltrials.gov/ct2/show/NCT04770935

May 9th, 2022 - Duration of each part of the study for one participant: Total study duration: Up to 57 days. Screening: up to 28 days. Up to 29 days of safety observation following the IV BIVV001 dose administration (this period includes PK sampling up to the fir...

A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
https://clinicaltrials.gov/ct2/show/NCT02932618

Apr 25th, 2022 - The main aim of the study is to check effectiveness, side effects, and tolerability of recombinant von Willebrand Factor (rVWF), with or without ADVATE, in the treatment and control of nonsurgical bleeding events in pediatric participants (less th...

A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)
https://clinicaltrials.gov/ct2/show/NCT03879135

Apr 21st, 2022 - The main aim of the study is to check effectiveness of rVWF (vonicog alfa) prophylaxis based on the annualized bleeding rate (ABR) of spontaneous (not related to trauma) bleeding episodes in pediatric and adult participants during the first 12 mon...

see more →

News  64 results

Women with von Willebrand disease: Managing menstrual and postpartum bleeding
https://www.mdedge.com/hematology-oncology/article/252066/bleeding-disorders/women-von-willebrand-disease-managing
Heidi Splete

Feb 23rd, 2022 - Hormonal therapy remains the most effective strategy for managing heavy menstrual bleeding in women with von Willebrand disease, based on data from one of three systematic reviews. Women with von Willebrand disease (VWD) experience many obstetric.

Infusion shown effective for acquired von Willebrand disease
https://www.mdedge.com/hematology-oncology/article/244070/bleeding-disorders/infusion-shown-effective-acquired-von
Mark S. Lesney, PhD

Aug 10th, 2021 - Acquired von Willebrand disease (aVWD) is a rare and serious condition associated with lymphoproliferative disorders, malignancy, autoimmune disorders, and cardiovascular disease. It is most commonly caused by monoclonal gammopathy of undetermined.

Novel molecule prolongs half-life of bleeding disorder treatments
https://www.mdedge.com/hematology-oncology/article/241963/bleeding-disorders/novel-molecule-prolongs-half-life-bleeding
Neil Osterweil

Jun 23rd, 2021 - A novel therapeutic approach using aptamers – short single strands of DNA or RNA designed to selectively bind to a target – shows promise for treating von Willebrand Disease (VWD), and other congenital bleed disorders such as hemophilia A, investi.

First year of life sees initial bleeding episodes in children with von Willebrand disease
https://www.mdedge.com/hematology-oncology/article/241277/bleeding-disorders/first-year-life-sees-initial-bleeding-episodes
Mark S. Lesney, PhD

Jun 9th, 2021 - To remedy a lack of data on infants and toddlers with von Willebrand disease (VWD), researchers examined data on patients collected from the U. S.

Type 3 von Willebrand a rare but serious bleeding disorder
https://www.mdedge.com/hematology-oncology/article/236987/bleeding-disorders/type-3-von-willebrand-rare-serious-bleeding
Neil Osterweil

Mar 10th, 2021 - Type 3 von Willebrand disease (VWD) is rare, but this form of the disease is associated with severe bleeding, particularly in muscles and joints, a bleeding disorders expert said. “There’s a virtually complete deficiency in von Willebrand factor [.

see more →

Patient Education  5 results see all →